期刊
PIGMENT CELL & MELANOMA RESEARCH
卷 34, 期 1, 页码 136-143出版社
WILEY
DOI: 10.1111/pcmr.12908
关键词
BRAF; cancer; CTTNB1; immunotherapy; KRAS; melanoma; molecular subtypes; neoantigen; NF1; NRAS; PDGFRA; PIK3CA; testis antigen
资金
- Auckland and Northland Branch of the Cancer Society of New Zealand
- Health Research Council of New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery
The study characterizes a panel of cell lines from metastatic melanomas, identifying four subgroups of cell lines based on gene expression profiles and detecting HLA haplotypes and neoantigens in the lines through immunogenotyping. The NZM panel serves as a valuable resource for understanding the diversity of melanoma biology and the responses of melanoma to therapeutic interventions.
Melanoma is a disease associated with a very high mutation burden and thus the possibility of a diverse range of oncogenic mechanisms that allow it to evade therapeutic interventions and the immune system. Here, we describe the characterization of a panel of 102 cell lines from metastatic melanomas (the NZM lines), including using whole-exome and RNA sequencing to analyse genetic variants and gene expression changes in a subset of this panel. Lines possessing all major melanoma genotypes were identified, and hierarchical clustering of gene expression profiles revealed four broad subgroups of cell lines. Immunogenotyping identified a range of HLA haplotypes as well as expression of neoantigens and cancer-testis antigens in the lines. Together, these characteristics make the NZM panel a valuable resource for cell-based, immunological and xenograft studies to better understand the diversity of melanoma biology and the responses of melanoma to therapeutic interventions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据